AGTC Announces Expansion of Clinical and Regulatory Leadership Teams
June 14 2018 - 4:01PM
20+ Year Medical Affairs and Ophthalmology
Veteran, Lanita C. Scott, M.D., Appointed as Vice President of
Clinical Research and Medical Affairs
Applied Genetic Technologies Corporation (NASDAQ:AGTC), a
biotechnology company conducting human clinical trials of
adeno-associated virus (AAV)-based gene therapies for the treatment
of rare diseases, today announced the appointments of Lanita C.
Scott, M.D., to the position of Vice President of Clinical Research
and Medical Affairs and Karen M. Carroll, RN, to the position of
Vice President of Clinical Development Operations.
"We are delighted to announce the continued
enhancement of our clinical and medical leadership teams with the
appointments of these two highly accomplished individuals, Dr.
Scott and Ms. Carroll," said Sue Washer, President and CEO of AGTC.
"Having the added expertise to efficiently execute quality clinical
trials and more effectively engage with physicians reinforces our
strong foundation and will further our success in developing gene
therapies aimed at treating rare, inherited retinal diseases.”
Dr. Scott brings more than 20 years of
experience in medical affairs to her new role, with a proven track
record in strategic research, product positioning, publication
planning, key opinion leader development and clinical trial design.
She also led her own ophthalmology/glaucoma private practice for
several years. Prior to joining AGTC, Dr. Scott served as Head,
Global Strategic Research, Senior Medical Director, and Global
Medical Affairs for Santen, Inc., where she successfully
implemented a Global Strategic Research function, including
organizational design, governance and infrastructure needs
assessment and resource recommendations. In addition, Dr. Scott
also served as Assistant Medical Director, Ophthalmology, for
leading biotech manufacturer Genentech, Inc., Associate Medical
Director, Medical Affairs, for Regeneron Pharmaceuticals, Inc., and
Senior Medical Director, Global Medical Affairs for Allergan,
Inc.
Ms. Carroll is a registered nurse and
experienced clinical operations professional, with extensive
experience in rare disease drug development. Most recently, she
served as Vice President of Clinical Operations at Promedior, where
she contributed to the successful business development deal with
Bristol Myers Squibb, completed enrollment of a global Phase 2
clinical trial ahead of schedule and lead the global team to
successful data read out. Prior to this, Ms. Carroll served
on the clinical operations team at Vertex, where she was selected
to reinvigorate the Incivek Phase 3 trial from delayed site
activation and enrollment, leading the team to complete the study
on time despite initial delays. While at Vertex, she also led the
Kalydeco Phase 3 startup team to record-breaking site start up and
activations. Ms. Carroll is a welcome addition to the AGTC
executive team as she brings a passion for fulfilling the unmet
needs of patients and an ability to lead successful clinical
development teams.
About AGTCAGTC is a clinical-stage
biotechnology company that uses a proprietary gene therapy platform
to develop transformational genetic therapies for patients
suffering from rare and debilitating diseases. Its initial
focus is in the field of ophthalmology, where it has active
clinical trials in X-linked retinoschisis (XLRS), X-linked
retinitis pigmentosa (XLRP), and achromatopsia (ACHM CNGB3 &
ACHM CNGA3). In addition to its clinical trials, AGTC has
preclinical programs in optogenetics, adrenoleukodystrophy (ALD),
which is a disease of the central nervous system (CNS), and
otology. The clinical-stage XLRS and XLRP programs, the discovery
program in ALD and two additional ophthalmology programs are being
developed in collaboration with Biogen. In addition to its product
pipeline, AGTC has a significant intellectual property portfolio
and extensive expertise in the design of gene therapy products
including capsids, promoters and expression cassettes, as well as
expertise in the formulation, manufacture and physical delivery of
gene therapy products.
Forward Looking StatementsThis
release contains forward-looking statements that reflect AGTC's
plans, estimates, assumptions and beliefs. Forward-looking
statements include information concerning possible or assumed
future results of operations, business strategies and operations,
preclinical and clinical product development and regulatory
progress, potential growth opportunities, potential market
opportunities and the effects of competition. Forward-looking
statements include all statements that are not historical facts and
can be identified by terms such as "anticipates," "believes,"
"could," "seeks," "estimates," "expects," "intends," "may,"
"plans," "potential," "predicts," "projects," "should," "will,"
"would" or similar expressions and the negatives of those terms.
Actual results could differ materially from those discussed in the
forward-looking statements, due to a number of important factors.
Risks and uncertainties that may cause actual results to differ
materially include, among others: gene therapy is still novel with
only a few approved treatments so far; AGTC cannot predict when or
if it will obtain regulatory approval to commercialize a product
candidate or receive reasonable reimbursement; uncertainty inherent
in clinical trials and the regulatory review process; risks and
uncertainties associated with drug development and
commercialization; factors that could cause actual results to
differ materially from those described in the forward-looking
statements are set forth under the heading "Risk Factors" in the
Company's Annual Report on Form 10-K for the fiscal year ended
September 13, 2017, as filed with the SEC. Given these
uncertainties, you should not place undue reliance on these
forward-looking statements. Also, forward-looking statements
represent management's plans, estimates, assumptions and beliefs
only as of the date of this release. Except as required by law, we
assume no obligation to update these forward-looking statements
publicly or to update the reasons actual results could differ
materially from those anticipated in these forward-looking
statements, even if new information becomes available in the
future.
IR/PR CONTACTS: David Carey (IR) or Tom
Vickery (PR) Lazar Partners Ltd. T: (212) 867-1768 or (646)
871-8482 dcarey@lazarpartners.com or tvickery@lazarpartners.com
Corporate Contact:Bill SullivanChief Financial
OfficerApplied Genetic Technologies CorporationT: (617)
843-5728 bsullivan@agtc.com
Stephen PotterChief Business OfficerApplied Genetic Technologies
CorporationT: (617) 413-2754spotter@agtc.com
Applied Genetic Technolo... (NASDAQ:AGTC)
Historical Stock Chart
From Mar 2024 to Apr 2024
Applied Genetic Technolo... (NASDAQ:AGTC)
Historical Stock Chart
From Apr 2023 to Apr 2024